

AMENDMENT TO THE CLAIMS

Please enter the following amendments to the claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents as follows:

Please cancel claims 4, 11, 14, 19 and 20 without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents.

1. (Currently Amended) A ~~targeted~~ recombinant adenovirus vector, comprising: (i) a gene encoding a heterologous protein; (ii) a wild-type Ad5 fiber protein comprising an immunoglobulin-binding domain of Staphylococcus aureus Protein A; and (iii) a gene encoding a fusion protein comprising a targeting ligand selected from the group consisting of CD40 ligand and a single chain fragment (scFv) of anti-human CD40 antibody and an immunoglobulin Fc domain, ~~wherein binding of said immunoglobulin-binding domain to said Fc domain connects said targeting ligand to said modified fiber protein, thereby targeting said adenovirus vector to a cell that expresses a cell surface molecule that binds to said targeting ligand.~~

2. (Cancelled)

3. (Currently Amended) The ~~targeted~~ adenovirus vector of claim 1, wherein said immunoglobulin-binding domain is inserted at the HI loop or the carboxy terminal of said fiber protein.

4. (Cancelled)

5. (Currently Amended) The ~~targeted~~ adenovirus vector of claim 1, wherein said fiber protein is a fiber-fibrin chimera, and said immunoglobulin-binding domain is inserted at the carboxy terminal of said fiber-fibrin chimera.

6. (Cancelled)

7. (Currently Amended) The ~~targeted~~ adenovirus vector of claim 1, wherein said heterologous protein is a tumor associated antigen.

8. (Currently Amended) The ~~targeted~~ adenovirus vector of claim 7, wherein said tumor associated antigen is prostate-specific membrane antigen.

9. (Currently Amended) A ~~CD40-targeted~~ recombinant adenovirus vector, comprising: (i) a gene encoding a heterologous protein; (ii) a modified fiber protein comprising an immunoglobulin-binding domain; and (iii) a gene encoding a fusion protein comprising an immunoglobulin Fc domain and a targeting ligand selected from the group consisting of CD40

ligand and a single chain fragment (scFv) of anti-human CD40 antibody, ~~wherein binding of said immunoglobulin-binding domain to said Fc domain connects said targeting ligand to said modified fiber protein, thereby targeting said adenovirus vector to a CD40⁺ cell.~~

10. (Currently Amended) The ~~targeted~~ adenovirus vector of claim 9, wherein said immunoglobulin-binding domain is inserted at the HI loop or the carboxy terminal of said fiber protein.

11. (Cancelled)

12. (Currently Amended) The ~~targeted~~ adenovirus vector of claim 9, wherein said immunoglobulin-binding domain is the Fc-binding domain of Staphylococcus aureus Protein A.

13. (Currently Amended) The ~~targeted~~ adenovirus vector of claim 9, wherein said fiber protein is a fiber-fibritin chimera, and said immunoglobulin-binding domain is inserted at the carboxy terminal of said fiber-fibritin chimera.

14. (Cancelled)

15. (Currently Amended) The ~~targeted~~ adenovirus vector of claim 9, wherein said anti-human CD40 antibody is G28.5.

16. (Currently Amended) The ~~targeted~~ adenovirus vector of claim 9, wherein said heterologous protein is a tumor associated antigen.

17. (Currently Amended) The ~~targeted~~ adenovirus vector of claim 16, wherein said tumor associated antigen is prostate-specific membrane antigen.

18. (Currently Amended) The ~~targeted~~ adenovirus vector of claim 9, wherein said gene encoding said heterologous protein and said gene encoding said fusion protein are operably linked to a dendritic cell-specific promoter.

19. (Cancelled)

20. (Cancelled)